Der Hautarzt

, Volume 58, Issue 6, pp 483–488

Prophylaktische und therapeutische HPV-Impfstoffe

Leitthema

Zusammenfassung

Seit mehr als 100 Jahren sind Papillomviren (PV) als ursächliche Erreger von gutartigen und malignen Erkrankungen bei Tieren bekannt. Es dauerte jedoch mehr als 20 Jahre, bis eine kausale Rolle dieser Viren auch beim Anogenitalkrebs des Menschen, besonders beim Zervixkarzinom, allgemein akzeptiert wurde. Intensive Forschungen führten in den letzten Jahren zur Entwicklung eines prophylaktischen Impfstoffs, der jetzt zur Verfügung steht. Die Möglichkeit einer HPV-spezifischen Immuntherapie muss noch untersucht werden.

Schlüsselwörter

Papillomviren Zervixkarzinom Prophylaktischer Impfstoff Therapeutischer Impfstoff HPV-Impfstoffe 

Prophylactic and therapeutic HPV immunization

Abstract

Papilloma viruses (PV) have been known to cause benign and malignant tumors in animals for more than 100 years. It took over 20 years to win general acceptance for their causative role in anogenital carcinomas in humans in particular in cervial carcinoma. Extensive research has led to the development of a prophylactic vaccine which is now commercially available. It remains to be investigated if HPV-specific therapeutic vaccines can be developed.

Keyword

Papilloma virus Cervical carcinoma Prophylactic vaccine Therapeutic vaccine HPV vaccine 

Literatur

  1. 1.
    Lowy D, Howley P (2001) Papillomaviruses. In: Knipe D, Howley P (eds) Fields virology. Williams and Wilkins, Lippincott, pp 2231–2264Google Scholar
  2. 2.
    Rigoni-Stern D (1842) Fatti statisici relativi alle malatie cancerose. G Serve Prog Pathol Terap 2: 507–517Google Scholar
  3. 3.
    Gagnon F (1950) Contribution to the study of the etiology and prevention of cancer of the cervix of the uterus. Am J Obstet Gynecol 60(3): 516–522PubMedGoogle Scholar
  4. 4.
    Taylor RS, Carroll BE, Lloyd JW (1959) Mortality among women in 3 Catholic religious orders with special reference to cancer. Cancer 12: 1207–1225CrossRefPubMedGoogle Scholar
  5. 5.
    Towne JE (1955) Carcinoma of the cervix in nulliparous and celibate women. Am J Obstet Gynecol 69(3): 606–613PubMedGoogle Scholar
  6. 6.
    Vonka V, Kanka J, Jelinek J et al. (1984) Prospective study on the relationship between cervical neoplasia and herpes simplex type-2 virus. I. Epidemiological characteristics. Int J Cancer 33(1): 49–60CrossRefPubMedGoogle Scholar
  7. 7.
    Licht W(1894) Om Vorters Smitsomhed. Ugeskrift Laeger 1: 368–369Google Scholar
  8. 8.
    Variot G (1894) Un cas d’inoculation experimentale des verruces de l’enfant a l’homme. J Clin Therapy Infant 2: 529–534Google Scholar
  9. 9.
    Ciuffo (1907) Innesto positivo con filtrato di verruca volgare. Giorn Ital Mal Venerol 48: 12–17Google Scholar
  10. 10.
    Waelsch L (1918) Übertragungsversuche mit spitzen Kondyloma. Arch Dermatol Syphilis 124: 625–646CrossRefGoogle Scholar
  11. 11.
    Shope R (1933) Infectious papillomatosis of rabbits; with a note on histopathology. J Exp Med 58: 607–624CrossRefGoogle Scholar
  12. 12.
    Ito Y, Evans CA (1965) Tumorigenic nucleic acid extracts from tissues of a transplantable carcinoma, Vx7. J Natl Cancer Inst 34: 431–437PubMedGoogle Scholar
  13. 13.
    zur Hausen H (1976) Condylomata acuminata and human genital cancer. Cancer Res 36(2 pt 2): 794PubMedGoogle Scholar
  14. 14.
    de Villiers EM, Gissmann L, zur Hausen H (1981) Molecular cloning of viral DNA from human genital warts. J Virology 40(3): 932–935PubMedGoogle Scholar
  15. 15.
    Gissmann L, Diehl V, Schultz-Coulon HJ, zur Hausen H (1982) Molecular cloning and characterization of human papilloma virus DNA derived from a laryngeal papilloma. J Virology 44(1): 393–400PubMedGoogle Scholar
  16. 16.
    Boshart M, Gissmann L, Ikenberg H et al. (1984) A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. Embo J 3(5): 1151–1157PubMedGoogle Scholar
  17. 17.
    Dürst M, Gissmann L, Ikenberg H, zur Hausen H (1983) A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA 80(12): 3812–3815CrossRefPubMedGoogle Scholar
  18. 18.
    Grigg W, Wilhelm G (1953) Epidemiological study of plantar warts among school children. Public Health Report US 68: 985–988Google Scholar
  19. 19.
    Findlay G (1930) Warts. In: A system of bacteriology in relation to medicine. H. M. Stationary Office, London, pp 252–258Google Scholar
  20. 20.
    Massing AM, Epstein WL (1963) Natural history of warts. A two-year study. Arch Dermatol 87: 306–310PubMedGoogle Scholar
  21. 21.
    Biberstein (1944) Immunization therapy of warts. Arch Dermatol Syphilol 50: 12–22Google Scholar
  22. 22.
    Penn I (1986) Cancers of the anogenital region in renal transplant recipients. Analysis of 65 cases. Cancer 58(3): 611–616CrossRefPubMedGoogle Scholar
  23. 23.
    Evans CA, Gorman LR, Ito Y, Weiser RS (1962) A vaccination procedure which increases the frequency of regressions of Shope papillomas of rabbits. Nature 193: 288–289CrossRefPubMedGoogle Scholar
  24. 24.
    Han R, Cladel NM, Reed CA et al. (1999) Protection of rabbits from viral challenge by gene gun-based intracutaneous vaccination with a combination of cottontail rabbit papillomavirus E1, E2, E6, and E7 genes. J Virology 73(8): 7039–7043PubMedGoogle Scholar
  25. 25.
    Han R, Reed CA, Cladel NM, Christensen ND (2000) Immunization of rabbits with cottontail rabbit papillomavirus E1 and E2 genes: protective immunity induced by gene gun-mediated intracutaneous delivery but not by intramuscular injection. Vaccine 18(26): 2937–2944CrossRefPubMedGoogle Scholar
  26. 26.
    Gissmann L, Osen W, Muller M, Jochmus I (2001) Therapeutic vaccines for human papillomaviruses. Intervirology 44(2–3): 167–175Google Scholar
  27. 27.
    Da Silva DM, Eiben GL, Fausch SC et al. (2001) Cervical cancer vaccines: emerging concepts and developments. J Cell Physiol 186(2): 169–182CrossRefPubMedGoogle Scholar
  28. 28.
    Eiben GL, da Silva DM, Fausch SC et al. (2003) Cervical cancer vaccines: recent advances in HPV research. Viral Immunol 16(2): 111–121CrossRefPubMedGoogle Scholar
  29. 29.
    Stanley MA (2003) Progress in prophylactic and therapeutic vaccines for human papillomavirus infection. Expert Rev Vaccines 2(3): 381–389CrossRefPubMedGoogle Scholar
  30. 30.
    Jarrett WF, O’Neil BW, Gaukroger JM et al. (1990) Studies on vaccination against papillomaviruses: the immunity after infection and vaccination with bovine papillomaviruses of different types. Vet Rec 126(19): 473–475PubMedGoogle Scholar
  31. 31.
    Roden RB, Weissinger EM, Henderson DW et al. (1994) Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins. J Virology 68(11): 7570–7574PubMedGoogle Scholar
  32. 32.
    Rose RC, Reichman RC, Bonnez W (1994) Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J Gen Virol 75 ( Pt 8): 2075–2079PubMedGoogle Scholar
  33. 33.
    Kreider JW, Howett MK, Leure-Dupree AE et al. (1987) Laboratory production in vivo of infectious human papillomavirus type 11. J Virology 61(2): 590–593PubMedGoogle Scholar
  34. 34.
    Pastrana DV, Buck CB, Pang YY et al. (2004) Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321(2): 205–216CrossRefPubMedGoogle Scholar
  35. 35.
    Pilacinski WP, Glassman DL, Glassman KF et al. (1986) Immunization against bovine papillomavirus infection. Ciba Found Symp 120: 136–156PubMedGoogle Scholar
  36. 36.
    Salunke DM, Caspar DL, Garcea RL (1986) Self-assembly of purified polyomavirus capsid protein VP1. Cell 46(6): 895–904CrossRefPubMedGoogle Scholar
  37. 37.
    Zhou J, Stenzel DJ, Sun XY, Frazer IH (1993) Synthesis and assembly of infectious bovine papillomavirus particles in vitro. J Gen Virol 74 (Pt 4): 763–876PubMedGoogle Scholar
  38. 38.
    Kirnbauer R, Taub J, Greenstone H et al. (1993) Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virology 67(12): 6929–6936PubMedGoogle Scholar
  39. 39.
    Bouwes Bavinck JN, Stark S, Petridis AK et al. (2000) The presence of antibodies against virus-like particles of epidermodysplasia verruciformis-associated humanpapillomavirus type 8 in patients with actinic keratoses. Br J Dermatol 142(1): 103–109CrossRefPubMedGoogle Scholar
  40. 40.
    Christensen ND, Cladel NM, Reed CA, Han R (2000) Rabbit oral papillomavirus complete genome sequence and immunity following genital infection. Virology 269(2): 451–461CrossRefPubMedGoogle Scholar
  41. 41.
    Combita AL, Bravo MM, Touze A et al. (2002) Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus-like particles in colombian women with invasive cervical cancer. Int J Cancer 97(6): 796–803CrossRefPubMedGoogle Scholar
  42. 42.
    Cuberos V, Perez J, Lopez CJ et al. (2006) Molecular and serological evidence of the epidemiological association of HPV 13 with focal epithelial hyperplasia: a case-control study. J Clin Virol 37(1): 21–26CrossRefPubMedGoogle Scholar
  43. 43.
    Cubie HA, Plumstead M, Zhang W et al. (1998) Presence of antibodies to human papillomavirus virus-like particles (VLPs) in 11–13-year-old schoolgirls. J Med Virol 56(3): 210–216CrossRefPubMedGoogle Scholar
  44. 44.
    Hagensee ME, Olson NH, Baker TS, Galloway DA (1994) Three-dimensional structure of vaccinia virus-produced human papillomavirus type 1 capsids. J Virology 68(7): 4503–4505PubMedGoogle Scholar
  45. 45.
    Schiller JT, Lowy DR (2001) Papillomavirus-like particle vaccines. J Natl Cancer Inst Monogr 28: 50–54PubMedGoogle Scholar
  46. 46.
    Ault KA, Giuliano AR, Edwards RP et al. (2004) A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. Vaccine 22(23–24): 3004–3007Google Scholar
  47. 47.
    Brown DR, Bryan JT, Schroeder JM et al. (2001) Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer. J Infect Dis 184(9): 1183–1186CrossRefPubMedGoogle Scholar
  48. 48.
    Emeny RT, Wheeler CM, Jansen KU et al. (2002) Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine. J Virology 76(15): 7832–7842CrossRefPubMedGoogle Scholar
  49. 49.
    Evans TG, Bonnez W, Rose RC et al. (2001) A phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J Infect Dis 183(10): 1485–1493CrossRefPubMedGoogle Scholar
  50. 50.
    Fife KH, Wheeler CM, Koutsky LA et al. (2004) Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women. Vaccine 22(21–22): 2943–2952Google Scholar
  51. 51.
    Harro CD, Pang YY, Roden RB et al. (2001) Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 93(4): 284–292CrossRefPubMedGoogle Scholar
  52. 52.
    Kirnbauer R, Chandrachud LM, O’Neil BW et al. (1996) Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 219(1): 37–44CrossRefPubMedGoogle Scholar
  53. 53.
    Lowe RS, Brown DR, Bryan JT et al. (1997) Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. J Infect Dis 176(5): 1141–1145PubMedGoogle Scholar
  54. 54.
    Palker TJ, Monteiro JM, Martin MM et al. (2001) Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles. Vaccine 19(27): 3733–3743CrossRefPubMedGoogle Scholar
  55. 55.
    Breitburd F, Kirnbauer R, Hubbert NL et al. (1995) Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virology 69(6): 3959–3963PubMedGoogle Scholar
  56. 56.
    Inglis S, Shaw A, Koenig S (2006) Chapter 11: HPV vaccines: Commercial Research & Development. Vaccine 24 [Suppl 3]: S99–S105Google Scholar
  57. 57.
    Ault KA (2005) Prophylactic use of quadrivalent human papillomavirus (HPV) (types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine reduces cervical intraepithelial neoplasia (CIN) 2/3 and adenocarcinoma in situ (AIS) risk, Supplements 3(4) (2005), 11. Eur J Cancer Supplements 3(4): 11–13Google Scholar
  58. 58.
    Harper DM, Franco EL, Wheeler C et al. (2004) Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364(9447): 1757–1765CrossRefPubMedGoogle Scholar
  59. 59.
    Koutsky LA, Ault KA, Wheeler CM et al. (2002) A controlled trial of a human papillomavirus type 16 vaccine. New Engl J Medicine 347(21): 1645–1651CrossRefGoogle Scholar
  60. 60.
    Mao C, Koutsky LA, Ault KA et al. (2005) Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstetrics Gynecol 107(1): 18–27Google Scholar
  61. 61.
    Villa LL, Costa RL, Petta CA et al. (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncology 6(5): 271–278CrossRefPubMedGoogle Scholar
  62. 62.
    Bratti MC, Rodriguez AC, Schiffman M et al. (2004) Description of a seven-year prospective study of human papillomavirus infection and cervical neoplasia among 10000 women in Guanacaste, Costa Rica. Revista panamericana de salud publica. Pan American J Public Health 15(2): 75–89Google Scholar
  63. 63.
    Lehtinen M, Paavonen J (2003) Effectiveness of preventive human papillomavirus vaccination. Internat J STD AIDS 14(12): 787–792CrossRefGoogle Scholar
  64. 64.
    Lazcano-Ponce E, Rivera L, Arillo-Santillan E et al. (2001) Acceptability of a human papillomavirus (HPV) trial vaccine among mothers of adolescents in Cuernavaca, Mexico. Arch Medical Res 32(3): 243–247CrossRefGoogle Scholar
  65. 65.
    Zimet GD, Mays RM, Winston Y et al. (2000) Acceptability of human papillomavirus immunization. J Women Health Gender-based Medicine 9(1): 47–50Google Scholar
  66. 66.
    Walboomers JM, Jacobs MV, Manos MM et al. (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathology 189(1): 12–19CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag 2007

Authors and Affiliations

  1. 1.Deutsches Krebsforschungszentrum HeidelbergHeidelbergDeutschland

Personalised recommendations